1. Home
  2. CNEY vs KPRX Comparison

CNEY vs KPRX Comparison

Compare CNEY & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CN Energy Group Inc.

CNEY

CN Energy Group Inc.

HOLD

Current Price

$0.60

Market Cap

11.3M

Sector

Industrials

ML Signal

HOLD

Logo Kiora Pharmaceuticals Inc.

KPRX

Kiora Pharmaceuticals Inc.

HOLD

Current Price

$2.14

Market Cap

9.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNEY
KPRX
Founded
2018
1998
Country
China
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.3M
9.2M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
CNEY
KPRX
Price
$0.60
$2.14
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
1.9M
52.7K
Earning Date
01-01-0001
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$36,049,275.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.64
$1.77
52 Week High
$12.23
$4.18

Technical Indicators

Market Signals
Indicator
CNEY
KPRX
Relative Strength Index (RSI) 13.40 47.41
Support Level $0.71 $2.00
Resistance Level $1.50 $2.23
Average True Range (ATR) 0.11 0.12
MACD -0.04 0.04
Stochastic Oscillator 2.52 67.78

Price Performance

Historical Comparison
CNEY
KPRX

About CNEY CN Energy Group Inc.

CN Energy Group Inc along with its subsidiaries is a manufacturer and supplier of wood-based activated carbon that is used in pharmaceutical manufacturing, industrial manufacturing, water purification, environmental protection, and food and beverage production and a producer of biomass electricity generated in the process of producing activated carbon. The firm generates a majority of its revenue from Activated carbon.

About KPRX Kiora Pharmaceuticals Inc.

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Share on Social Networks: